Data / Form D filings / K2 Biolabs, Inc.
K2 Biolabs, Inc.: Form D filings
K2 Biolabs, Inc., a biotechnology company in Houston, TX, filed 2 Form D notices with the SEC between 2021 and 2023. The latest, on August 2, 2023, reports $615,522 sold of a $3 million offering to 7 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2710 Reed Road , Ste. 160, Houston, TX, 77051
- Phone
- (347) 752-3124
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2021
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1848448
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 2, 2023 | New notice | $3,000,000 | $615,522 | $2,384,478 | 7 | Jun 5, 2023 | sec.gov |
| Mar 12, 2021 | New notice | $5,500,000 | $5,500,000 | 40 | Mar 1, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Andrew DeSomma | Director | |
| Gerard Fleury | Director | |
| Clifford J. Stocks | Director | |
| Andrew J. Strong | Director | |
| Daniel J. Clark | Executive Officer | |
| Kevin Slawin | Director | |
| Kieron Jones | Director, Executive Officer |
Other biotechnology companies in Texas that filed recently
- Nuclein, LLC $15.7 million · Oct 27, 2026
- OncoNano Medicine, Inc. $10.1 million · Oct 8, 2026
- Solaris Endovascular Inc. $5 million · Oct 1, 2026
- Hera Biotech, Inc. $1.7 million · Sep 23, 2026
- Kayak Therapeutics, Inc. $25 million · Aug 21, 2026
- InnovoTEX Inc. $2.7 million · Aug 18, 2026
Every Form D from the week of Jul 31, 2023 · All recent filings in Texas · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what K2 Biolabs, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.